All PlansCoverageLow impact
Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease
Blue Cross & Blue Shield of Mississippi·MS · Cardiology, Internal Medicine, Family Medicine·Medical Policy
Effective date
Jul 31, 2025
We identified it
Jun 20, 2026
Summary
This policy confirms that gene expression testing for stable ischemic heart disease evaluation remains investigational and non-covered. The policy was recently reviewed with no changes, maintaining that these tests are not considered medically necessary.
Action Required
Immediately: Continue denying coverage for gene expression testing CPT codes 81493 and 84999 when used for stable ischemic heart disease evaluation. Billing team should ensure these codes are flagged as investigational/non-covered in system. Inform providers that these tests remain non-covered and claims will be denied.